# Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)

> **NCT07073183** · PHASE1 · NOT_YET_RECRUITING · sponsor: **CureVac** · enrollment: 36 (estimated)

## Conditions studied

- Squamous NSCLC

## Interventions

- **BIOLOGICAL:** CV09070101 mRNA vaccine (CVHNLC) 50 µg
- **BIOLOGICAL:** CV09070101 mRNA vaccine (CVHNLC) 100 µg
- **BIOLOGICAL:** CV09070101 mRNA vaccine (CVHNLC) 200 µg
- **BIOLOGICAL:** CV09070101 mRNA vaccine (CVHNLC) 400 µg
- **BIOLOGICAL:** CV09070101 mRNA vaccine (CVHNLC) 400 µg

## Key facts

- **NCT ID:** NCT07073183
- **Lead sponsor:** CureVac
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-30
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07073183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07073183, "Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07073183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*